209P Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer

ESMO rare cancers. 2026 Open access

Read full text
Authors: Daniel H. Orbach, Rui Xu, C. Qi, Christian Michel Zwaan, Ray McDermott, Antoîne Italiano, M. Tahara, M. Casanova, D-I. Burcoveanu, Kelly Guiver, Natascha Neu, C.E. Mussi
+4 more E. De La Cuesta, Theodore Willis Laetsch, A. Drilon, David S. Hong
DOI: 10.1016/j.esmorc.2026.100415
Cited by: 0

Abstract

Larotrectinib (laro) is a first-in-class, highly selective, central nervous system (CNS)-active TRK inhibitor approved for tumour-agnostic use in TRK fusion cancer. Here, we report data on patients (pts) with treatment-naïve TRK fusion cancer.

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Sarcoma Diagnosis and Treatment Cancer Genomics and Diagnostics

Publication details

Journal / source
ESMO rare cancers.
Volume
5
Pages
100415–100415
Publication date
1 March 2026
Language
EN